General Information of Drug (ID: DMBR5Q7)

Drug Name
Rolitetracycline Drug Info
Synonyms
Bristacin; Kinteto; Pyrrolidinomethyltetracycline; Reverin; Revrin; Rolitetraciclina; Rolitetracyclinum; Solvocillin; Superciclin; Synotodecin; Synterin; Syntetrex; Syntetrin; Tetraverin; Transcycline; Velacicline; Velacycline; AAT 4; SQ 15659; Pirrolidinometil-tetraciclina; Pirrolidinometil-tetraciclina [Italian]; Prm-TC; Rolitetraciclina [INN-Spanish]; Rolitetracyclinum [INN-Latin]; SQ 15,659; Synterin (TN); N-(Pyrrolidinomethyl)tetracycline; Pyrrolidino-methyl-tetracycline; N-Pyrrolidino-methyl-tetracycline; Rolitetracycline (JAN/USAN/INN); Rolitetracycline [USAN:INN:BAN:JAN]; N-(1-Pyrrolidinylmethyl)-tetracycline; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
54682938
ChEBI ID
CHEBI:63334
CAS Number
CAS 751-97-3
TTD Drug ID
DMBR5Q7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tetracycline DMZA017 Acne vulgaris ED80 Approved [2]
Framycetin DMF8DNE Acute liver failure DB91 Approved [3]
Netilmicin DMRD1QK Bacterial infection 1A00-1C4Z Approved [4]
Amikacin DM5PDRB Bacteremia 1A73 Approved [5]
Clomocycline DM0ZRMQ Bacterial infection 1A00-1C4Z Approved [6]
Spectinomycin DM0MQ35 Acute gonococcal cervicitis Approved [7]
Paromomycin DM1AGXN Amoebiasis 1A36 Approved [8]
Lymecycline DMOMLHJ Bacterial infection 1A00-1C4Z Approved [9]
Meclocycline DMSFQ8I Bacterial infection 1A00-1C4Z Approved [10]
Minocycline DMVN5OH Acne vulgaris ED80 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [1]

References

1 Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16.
2 The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
3 Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9.
4 Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6.
5 Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9.
6 Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5.
7 Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
8 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
9 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
10 Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
11 Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.